Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations

July 21, 2020
- $32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners - - Registration-Enabling Phase 2 CRESTONE Study Now…
READ MORE

Poseida Therapeutics Announces Pricing of Initial Public Offering

July 9, 2020
SAN DIEGO, July 9, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity…
READ MORE

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials

July 6, 2020
First patient dosed in AVROBIO’s global Phase 1/2 clinical trial of AVR-RD-02 for Gaucher disease type 1 Second patient dosed in investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis CAMBRIDGE,…
READ MORE